What question did this study set out to answer?

The aim is to evaluate the protective effect of a synthetic glycoconjugate vaccine against S. pneumoniae pneumonia.

The synthetic streptococcus pneumoniae oligosaccharide conjugate protected mice from severe pneumonia

View Full Paper

Ask AI

Bookmark

The aim is to evaluate the protective effect of a synthetic glycoconjugate vaccine against S. pneumoniae pneumonia.
Mice immunised subcutaneously with a synthetic glycoconjugate of S. pneumoniae serotype 3.
Use of an adjuvant (aluminium hydroxide) during immunisation.
Mice were boosted twice at two-week intervals before transnasal infection with S. pneumoniae.
Assessment included measuring specific antibody production and bacterial load post-infection.
Vaccinated mice produced specific antibodies against serotype 3 oligosaccharide.
Non-vaccinated controls exhibited hypothermia and weight loss, while vaccinated mice with alum did not.
Bacterial load was significantly reduced in mice vaccinated with glycoconjugate and alum.
Cytokine release was decreased in the bronchoalveolar space of the vaccinated mice.

No takes yet. Share an insight, caveat, or question.

Pilot study shows glyconjugate vaccine reduces pneumonia severity in mice, suggesting potential for broader vaccine use.

Reppe et al. (2014) studied this question.

View Full Paper

Ask AI

Bookmark